Bill Gunderson

It was only after my long career as a pharmacological scientist that I decided to pick the biotech and pharmaceutical stocks as the hottest industries of the year.

That, of course, is not true – the part about my career as a scientist, that is.

But I have been talking about, writing about, and – most importantly – investing in stocks for my clients and myself for a long time. And you do not have to be a scientist or doctor to invest in scientific or medical progress.

Of the nearly 3,800 stocks I cover in my Best Stocks Now app, most do not get white hot overnight. Neither do they lose all their value overnight.

So I look for industries first, then companies within those industries, when I am selecting investments. And I use my Best Stocks Now app.

That is how I found Anacor Pharmaceuticals — ANAC.

Data from Best Stocks NowApp

I didn’t hear about ANAC from a televised talking head. Nor did I read about in the Wall Street Journal or Barron’s. I found it with my Best Stocks Now app.

ANAC is in the Atopic Dermatitis business. Eczema. One of their products is getting some good results and some even say it could be a new standard of treatment for this disease.

But just because something is a good company in a good industry with a good – even great – product, it does not necessarily mean it is a good stock.

ANAC became public in 2010 at $5 per share. I noticed it three months ago when it hit #23 on my Best Stocks Now app. Looking at the chart, we see it has a powerful saucer pattern from April until Mid-August of this year when ANAC broke out and rose up the ranks in the Best Stocks Now app.

Let’s look at the company a bit more closely:


ANAC has a market cap of $665 million. It’s no Merck (MRK) or Johnson & Johson (JNJ). If it were, we would not be talking about it right now. Smaller biotech’s have been ruling the market this year.

Bill Gunderson

Bill Gunderson is the CEO and Chief Market Strategist of Gunderson Capital Managment in San Diego, CA. He is also a professional money manager, former research analyst, author of Best Stocks Now.

Due to the overwhelming enthusiasm of our readers it has become necessary to transfer our commenting system to a more scalable system in order handle the content.